Frontiers in oncology · 2026
Synchronous primary breast invasive carcinoma and breast metastasis from high-grade serous ovarian carcinoma: a case report and literature review.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Miao Jingge, Liu Nianqiu, Gong Fuhong, Chen Jiayi, Wang Chenxi, Lin Mengping, Li Na, Chen Yilin, Ge Fei, Chen Wenlin
Аннотация
BACKGROUND: Breast metastasis from high-grade serous ovarian carcinoma is rare, and its coexistence with a synchronous primary breast carcinoma is exceptionally uncommon. Distinguishing metastatic ovarian carcinoma from primary breast carcinoma is clinically important because treatment strategies and prognosis differ substantially.
CASE PRESENTATION: We report a 48-year-old premenopausal woman who presented with pleural effusion, abdominal distension, bilateral adnexal masses, multiple breast nodules, and systemic lymphadenopathy. Pathological examination of the pelvic lesion supported high-grade serous carcinoma, whereas breast biopsy demonstrated two morphologically distinct adenocarcinoma components. Immunohistochemical profiling, including breast-lineage markers and Müllerian/ovarian markers, supported the coexistence of primary breast invasive carcinoma and metastatic ovarian carcinoma involving the breast.
INTERVENTION AND OUTCOME: The patient was diagnosed with FIGO stage IVB high-grade serous ovarian carcinoma with breast, pleural, peritoneal, and lymph node involvement, synchronous with primary breast carcinoma. She received neoadjuvant paclitaxel plus carboplatin and achieved a partial response, followed by interval cytoreductive surgery, additional chemotherapy combined with bevacizumab, breast tumor excision, and maintenance therapy with fluzoparib plus bevacizumab. At the last follow-up on December 20, 2025, no evidence of disease progression was observed.
CONCLUSION: This case highlights the diagnostic difficulty of breast lesions in patients with ovarian carcinoma. Morphology combined with an appropriate immunohistochemical panel is essential for distinguishing primary breast carcinoma from metastatic ovarian carcinoma. Multidisciplinary evaluation and genetic assessment should be considered in similar cases.
CASE PRESENTATION: We report a 48-year-old premenopausal woman who presented with pleural effusion, abdominal distension, bilateral adnexal masses, multiple breast nodules, and systemic lymphadenopathy. Pathological examination of the pelvic lesion supported high-grade serous carcinoma, whereas breast biopsy demonstrated two morphologically distinct adenocarcinoma components. Immunohistochemical profiling, including breast-lineage markers and Müllerian/ovarian markers, supported the coexistence of primary breast invasive carcinoma and metastatic ovarian carcinoma involving the breast.
INTERVENTION AND OUTCOME: The patient was diagnosed with FIGO stage IVB high-grade serous ovarian carcinoma with breast, pleural, peritoneal, and lymph node involvement, synchronous with primary breast carcinoma. She received neoadjuvant paclitaxel plus carboplatin and achieved a partial response, followed by interval cytoreductive surgery, additional chemotherapy combined with bevacizumab, breast tumor excision, and maintenance therapy with fluzoparib plus bevacizumab. At the last follow-up on December 20, 2025, no evidence of disease progression was observed.
CONCLUSION: This case highlights the diagnostic difficulty of breast lesions in patients with ovarian carcinoma. Morphology combined with an appropriate immunohistochemical panel is essential for distinguishing primary breast carcinoma from metastatic ovarian carcinoma. Multidisciplinary evaluation and genetic assessment should be considered in similar cases.